Clinical TrialsBOLD will be discontinuing current monotherapy and combination arms of BBI-355 in the Phase 1/2 POTENTIATE clinical trial based on a narrow therapeutic index observed with Q2D dosing.
Diagnostic DelaysThe validation of the ecDNA hypothesis with the ECHO diagnostic tool has also been delayed, suggesting the investment thesis may remain in limbo until a new asset, such as the BBI-940, is developed.
Program DevelopmentThe shift in development results in a major setback for BOLD's lead program, as the agent returns to proof-of-principle and dose-optimization efforts and novel combination strategies to improve the therapeutic index.